DTB: Vol 31 No 4

Content tools

Share it

Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity

Bol Inf Farmacoter Navar. 2023;31 (4):1-19
https://doi.org/10.54095/BITN20233104EN

Download pdf

Table-1 Table-2 Table-3 Table-4 Table-5

The role of GLP1a in therapeutic medicine remains to be clearly defined, therefore the prescription thereof should be restricted to the sub-groups that will achieve the greatest benefit. Accessibility to lifestyle interventions should be ensured. The solution to the obesity epidemic requires political intervention regarding the social factors that promote it.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name

Current position or occupation

Place of work

Suggestions/Comments

Authors:

SANTI ARANA BALLESTAR
Family and Community Medicine resident
Centro de Salud Parque Goya (Zaragoza)

CRUZ BARTOLOMÉ MORENO
Family and Community Medicine Specialist
Centro de Salud Parque Goya (Zaragoza)

Family and Community Care Teaching Unit. Sector Zaragoza I

navarra.es

DTB: Vol 31 No 4

Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity